Atlas Trials

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Clinical trial NCT04681287 · UNKNOWN

Trial details

NCT number
NCT04681287
Sponsor
Henan Cancer Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
HER2 Positive Metastatic Breast Cancer
Start date
2021-04-23
Primary completion
2021-11-04
Enrollment
46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.